Coordinated topoisomerase function shapes the fluoroquinolone response of Chlamydia trachomatis

This study demonstrates that the fluoroquinolone susceptibility of *Chlamydia trachomatis* is determined by stage-dependent DNA supercoiling levels, where moxifloxacin-induced disruption of coordinated gyrase and TopA activity drives developmental arrest and persistence phenotypes.

The Gist

The Big Picture: A Bacterial Balancing Act

Imagine Chlamydia trachomatis (a common bacteria causing sexually transmitted infections) as a tiny construction crew building a house inside your cells. To build this house, the crew needs to unroll a massive, tangled ball of blueprints (DNA) and read them to make new parts.

In the bacterial world, this DNA isn't just lying flat; it's tightly wound like a rubber band. This winding is called supercoiling.

• Too loose: The blueprints fall apart and can't be read.
• Too tight: The blueprints snap or get stuck.
• Just right: The crew can work efficiently.

Two main "mechanics" keep this rubber band at the perfect tension:

1. DNA Gyrase: The mechanic that twists the rubber band tighter (adds tension).
2. Topoisomerase I (TopA): The mechanic that loosens the twist to prevent snapping (relaxes tension).

The researchers wanted to know what happens when you throw a wrench into this system using a powerful antibiotic called Moxifloxacin.

---

The Experiment: Timing is Everything

The scientists treated the bacteria with the antibiotic at different times during their "construction day" (their life cycle). They found that when you hit them with the drug matters just as much as how much you hit them.

1. The Early Morning (Early Stage)

• What happened: If they added the drug right when the bacteria started waking up, the bacteria died immediately.
• The Analogy: Imagine trying to build a house before you've even unpacked your tools. The antibiotic stopped the "unwinding" of the DNA blueprints instantly. The crew couldn't start, so the project was abandoned.

2. The Lunch Break (Mid-Cycle)

• What happened: If they added the drug while the bacteria were in the middle of copying their DNA (the busiest time), the bacteria didn't die immediately. Instead, they got weirdly large, stopped growing, and became "zombies."
• The Analogy: Imagine the construction crew is in the middle of pouring concrete. Suddenly, the cement truck (the antibiotic) jams the machinery. The crew can't finish the job, but they don't die either. They just sit there, swollen and stuck, waiting for the problem to fix itself. This is called a persistent state. They are alive but not infectious.
• The Twist: If you remove the antibiotic later, these "zombie" bacteria can wake up and start building again. This explains why some infections come back even after treatment.

3. The Late Afternoon (Late Stage)

• What happened: If they added the drug near the end of the cycle, the bacteria barely noticed.
• The Analogy: The house is already built, and the crew is packing up. The rubber bands are being re-wound for storage. Since they aren't actively reading the blueprints anymore, the antibiotic has little effect.

---

The Mechanism: How the Antibiotic Breaks the System

The antibiotic (Moxifloxacin) works by trapping the DNA Gyrase mechanic. It's like the antibiotic glues the mechanic's hands to the rubber band.

1. The Trap: The bacteria try to fix the DNA, but the antibiotic holds the "twisting" tool in place.
2. The Panic: The bacteria sense the DNA is getting too loose (relaxed). In a normal scenario, they would panic and order more "twisting" tools (Gyrase) to fix it.
3. The Paradox: The bacteria did order more tools (their DNA instructions for making Gyrase went up), but the antibiotic kept trapping the new tools immediately. So, the bacteria ended up with no working Gyrase.
4. The Domino Effect: Without Gyrase, the DNA gets too loose. To prevent total chaos, the bacteria also turned down their "loosening" mechanic (TopA). They tried to balance the scales by turning down both sides, but the antibiotic had already tipped the ship.

The Result: A Change in Personality

Because the DNA tension was messed up, the bacteria changed their behavior. They stopped making the "weapons" they usually use to infect new cells (proteins like OmpA) and started making "survival gear" (stress proteins like GroESL).

• Analogy: It's like a construction crew that, realizing their tools are broken, stops trying to build the house and instead puts on heavy coats and huddles together to wait out the storm. They aren't trying to infect you anymore; they are just trying to survive.

Why This Matters

This study solves a mystery: Why do some Chlamydia infections come back?

It turns out that the bacteria aren't necessarily "resistant" (immune) to the drug. Instead, they are adaptable. When the antibiotic hits them at the right time, they switch into a "survival mode" (persistence). They stop growing, hide, and wait for the drug to leave. Once the drug is gone, they wake up and start the infection all over again.

The Takeaway:
To cure these stubborn infections, we might need to do more than just kill the bacteria. We might need to find a way to stop them from switching into this "survival mode" or to wake them up so the antibiotic can finish the job. The key to unlocking this is understanding how they manage the tension of their DNA blueprints.

Technical Summary

1. Problem Statement

Chlamydia trachomatis (Ctr) is a leading cause of bacterial sexually transmitted infections and a significant public health burden. A major clinical challenge is the persistence of Ctr under antimicrobial pressure, leading to recurrent infections and treatment failure. While fluoroquinolones (e.g., moxifloxacin) target bacterial DNA gyrase, the mechanisms by which Ctr adapts to this stress, enters a persistent state, or develops tolerance remain poorly understood. Specifically, the role of DNA supercoiling homeostasis—maintained by the opposing activities of DNA gyrase (introduces negative supercoils) and Topoisomerase I (TopA, relaxes supercoils)—in shaping the bacterium's developmental cycle and antibiotic response is not fully elucidated.

2. Methodology

The study utilized the C. trachomatis L2 strain (including wild-type and reporter strains) infecting HeLa 229 cells. The experimental design focused on the developmental cycle (Elementary Bodies [EB] to Reticulate Bodies [RB] and back) and the effects of the fluoroquinolone moxifloxacin (Mox).

• Developmental Stage-Specific Treatment: Mox was added at specific time points post-infection (hpi): 0, 8, 16, and 24 hours to correlate drug sensitivity with distinct DNA supercoiling states (low, increasing, peak, and declining).
• Phenotypic Analysis:
  • Microscopy & Flow Cytometry: Used to assess inclusion size, morphology, and fluorescence intensity of reporter strains (GFP/mCherry) driven by specific promoters (ompA, omcA, groES).
  • Inclusion Forming Unit (IFU) Assay: Quantified infectious progeny production.
  • Reversibility Test: Cultures treated with Mox were transferred to drug-free media to distinguish between lethal damage and reversible persistence.
• Molecular Analysis:
  • qPCR: Quantified chlamydial genomic DNA (CtgDNA) accumulation to measure replication rates (comparing oriC-proximal vs. ter-proximal loci).
  • RT-qPCR: Measured transcript levels of topoisomerase genes (gyrAB, parCE, topA) and virulence genes (ompA, groESL1).
  • Immunoblotting: Assessed protein levels of GyrA, TopA, and stress chaperone Hsp60. A novel rabbit polyclonal anti-GyrA antibody was generated for this study.
  • Controls: Ampicillin was used as a control to induce envelope stress (distinct from topological stress) to differentiate specific topological responses from general stress responses.

3. Key Results

A. Stage-Dependent Susceptibility and Persistence

• Early Stage (0–8 hpi): Mox exposure completely halted bacterial growth and inclusion formation, indicating high vulnerability when the EB chromosome is decondensing.
• Mid-Cycle (16 hpi): Mox treatment resulted in enlarged, aberrant "persistent" forms, a sharp reduction in infectious EB progeny, and loss of the EB-specific protein OmcB. Crucially, this state was reversible; upon drug removal, bacteria resumed growth and produced progeny.
• Late Stage (24 hpi): Mox caused only mild defects, correlating with chromosome re-condensation and reduced reliance on gyrase.

B. Inhibition of DNA Replication

• Mox exposure during the exponential phase (8–24 hpi) caused a rapid, dose-dependent reduction in total CtgDNA accumulation.
• Both oriC-proximal and ter-proximal loci showed reduced replication, confirming that Mox-induced topological stress causes a global halt in DNA replication forks.

C. Differential Topoisomerase Regulation

• Transcriptional Response: Mox exposure triggered a rapid, dose-dependent upregulation of gyrAB transcripts, suggesting a compensatory attempt to restore negative supercoiling. In contrast, topA and parCE transcript levels remained largely unchanged.
• Protein Depletion: Despite increased gyrAB transcription, GyrA protein levels were depleted in a concentration-dependent manner. This is attributed to the trapping of GyrA in stable, drug-bound cleavage complexes (a known mechanism of fluoroquinolones).
• Coordinated Loss: Mox treatment also led to a reduction in TopA protein levels. This coordinated depletion of both enzymes (gyrase and TopA) was specific to topological stress; ampicillin-induced envelope stress did not cause the same simultaneous reduction, confirming Ctr can distinguish topological stress from other stressors.

D. Promoter-Specific Transcriptional Reprogramming

• Gene-Specific Responses: Supercoiling disruption did not cause uniform repression.
  • ompA (Major Outer Membrane Protein): Transcripts were rapidly repressed and remained low, even after 8 hours.
  • groESL1 (Heat Shock Operon): Transcripts initially dropped but then sharply increased after 8 hours of Mox exposure.
• Reporter Analysis: Dual-reporter strains confirmed that the groES promoter (stress response) remained active or increased under Mox, while the omcA promoter (developmental) was suppressed. This indicates that promoter architecture encodes specific sensitivity to superhelical density, allowing Ctr to prioritize stress adaptation over developmental progression.

4. Key Contributions

1. Mechanistic Link: Established a direct causal link between DNA supercoiling homeostasis and fluoroquinolone tolerance/persistence in C. trachomatis.
2. Stage-Specificity: Demonstrated that susceptibility is not static but depends on the developmental stage and the intrinsic supercoiling levels of the bacterium.
3. Coordinated Enzyme Regulation: Revealed a unique regulatory mechanism where Ctr responds to gyrase inhibition by simultaneously downregulating TopA protein levels, likely to prevent excessive DNA relaxation when negative supercoiling cannot be restored.
4. Transcriptional Plasticity: Showed that Ctr uses DNA topology as a primary regulatory axis to differentially reprogram gene expression (repressing growth/virulence genes while inducing stress chaperones) without relying on a large repertoire of transcription factors.

5. Significance

• Clinical Implications: The findings explain why fluoroquinolones may fail to eradicate C. trachomatis in vivo, as mid-cycle bacteria can enter a reversible persistent state rather than dying.
• Therapeutic Targets: The study identifies coordinated topoisomerase activity (specifically the balance between GyrA and TopA) as a critical vulnerability. Strategies that disrupt this balance or prevent the transition to persistence could enhance antibiotic efficacy.
• Fundamental Biology: The research highlights DNA supercoiling as a central, global regulator of chlamydial development and stress adaptation, offering a new paradigm for understanding bacterial persistence in obligate intracellular pathogens.